Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs AC 083 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; First in man
- Sponsors Actelion Pharmaceuticals
- 13 Jan 2017 Status changed from recruiting to completed.
- 01 Nov 2016 Planned number of patients changed from 48 to 72.
- 01 Nov 2016 Status changed from active, no longer recruiting to recruiting.